United States securities and exchange commission logo





                              April 27, 2020

       Alane Barnes
       Senior Vice President and Chief Legal Officer
       BioCryst Pharmaceuticals, Inc.
       4505 Emperor Boulevard, Suite 200
       Durham, North Carolina 27703

                                                        Re: BioCryst
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed April 24,
2020
                                                            File No. 333-237820

       Dear Ms. Barnes:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-3

       Risk Factors, page 2

   1.                                                   We note your disclosure
on page 6 regarding the exclusive forum provision in your
                                                        bylaws. Please include
a risk factor on this exclusive forum provision that discusses the
                                                        risks and implications
of the provision. In addition to any other material risks, please
                                                        discuss any potential
costs, unfavorable rulings, or uncertainty with regard to
                                                        enforcement. In this
regard, please refer to our comment below.
       Descriptio of Common Stock, Preferred Stock and Depositary Shares, page
6

   2.                                                   We note that your forum
selection provision discussed in your disclosure here and in
                                                        Article 8 of your
bylaws identifies the Court of Chancery of the State of Delaware as the
                                                        exclusive forum for
certain litigation, including any "derivative action." Please disclose
 Alane Barnes
BioCryst Pharmaceuticals, Inc.
April 27, 2020
Page 2
         whether this provision applies to actions arising under the Exchange
Act and the
         Securities Act. We note in this regard that Section 27 of the Exchange
Act creates
         exclusive federal jurisdiction over all suits brought to enforce any
duty or liability created
         by the Exchange Act or the rules or regulations thereunder. If this
provision does not
         apply to actions arising under the Exchange Act, please tell us how
you will inform
         investors in future filings that the provision does not apply to any
actions arising under the
         Exchange Act. If you intend for this provision to apply to the
Securities Act, please also
         revise your prospectus to state that there is uncertainty as to
whether a court would
         enforce such provision and that investors cannot waive compliance with
the federal
         securities laws and the rules and regulations thereunder.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Courtney Lindsay at (202) 551-7237 or Celeste Murphy at
(202) 551-3257
with any other questions.



FirstName LastNameAlane Barnes                                  Sincerely,
Comapany NameBioCryst Pharmaceuticals, Inc.
                                                                Division of
Corporation Finance
April 27, 2020 Page 2                                           Office of Life
Sciences
FirstName LastName